Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV) Covered Calls
You can sell covered calls on Enlivex Therapeutics Ltd. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ENLV (prices last updated Mon 4:16 PM ET):
| Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 1.08 | -0.02 | 1.01 | 1.09 | 48K | - | 0.0 |
| Covered Calls For Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Feb 21 | 2.5 | 0.00 | 1.09 | 0.0% | 0.0% | |
| Mar 21 | 2.5 | 0.00 | 1.09 | 0.0% | 0.0% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
| Top 10 Open Interest For Feb 21 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | TSLA covered calls | 1. | LUMN covered calls | |
| 2. | TLT covered calls | 7. | SLV covered calls | 2. | SNAP covered calls | |
| 3. | SPY covered calls | 8. | QQQ covered calls | 3. | QUBT covered calls | |
| 4. | IWM covered calls | 9. | KWEB covered calls | 4. | ENPH covered calls | |
| 5. | FXI covered calls | 10. | IBIT covered calls | 5. | SYM covered calls | |
Want more examples? ENIC Covered Calls | ENPH Covered Calls
